ELIQUIS (apixaban) 5mg tablets by Bristol-Myers Squibb and Pfizer Bristol-Myers Squibb and Pfizer announced that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application ...

Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...

Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...

ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One ...

(HealthDay News) — For patients in the Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) trial, the 5 mg twice daily dose of apixaban is ...

Credit: Getty Images. The recall is specific to Eliquis 5mg Tablets (60-count bottle) Lot# HN0063 with expiration date of September 2019. Bristol-Myers Squibb is recalling one lot of Eliquis (apixaban ...

Whether or not Eliquis 5mg* twice daily is non-inferior or superior to VKAs for the outcome of major or CRNM bleeding, as defined by the International Society on Thrombosis and Haemostasis (ISTH), in ...

Favorable safety shown in secondary prevention for acute venous thromboembolism ...

In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control ...

Choice of direct oral anticoagulant (DOAC) mattered for clinical outcomes among adults with atrial fibrillation (Afib), a study based on U.S. insurance claims found. Apixaban (Eliquis) users had ...

Pfizer and Bristol-Myers Squibb have reported that an extra year of treatment with their anticoagulant Eliquis (apixaban) safely reduces long-term risk in patients suffering from venous ...